Archive: February 2022

Evolving Management of Patients With Double-Hit Lymphoma

H&O  What is the definition of double-hit lymphoma? AL  Double-hit lymphoma is an aggressive B-cell lymphoma with MYC translocation and a BCL2 and/or BCL6 translocation. The […]

The Role of Minimal Residual Disease in Chronic Lymphocytic Leukemia

Abstract: Minimal residual disease (MRD) has evolved as a sensitive and highly prognostic surrogate parameter of response to therapy in chronic lymphocytic leukemia (CLL). Multiple methods […]

Current and Emerging Immunotherapies for Recurrent Cervical Cancer

Abstract: Approximately 4290 women in the United States and 311,000 women worldwide died of cervical cancer in 2021. The management of advanced, recurrent, and/or metastatic cervical […]

When to Use Germline Genetic Testing in Prostate Cancer

H&O  What germline DNA repair gene mutations play a role in prostate cancer? VG  Many DNA repair genes play a role in hereditary prostate cancer. These […]

Letter From the Editor: An Open Letter to Dr Fauci

Dear Dr Fauci, I would like to commend you on the phenomenal job you have been doing as chief medical advisor to the President during the […]

Sequencing Strategies in the Management of Metastatic Colorectal Cancer With HER2 Amplification

H&O  How common is HER2 amplification in metastatic colorectal cancer (CRC)? KR  HER2 amplification is seen in approximately 2% to 3% of unselected patients with CRC. […]

Barriers to Adherence to Oral Drug Regimens in Oncology and Strategies for Improvement

H&O  How common are oral drugs in oncology? JB  Approximately 25% to 35% of the drugs currently used in oncology are administered orally. Most of the […]

Back to Archive